Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
- Resource Type
- Article
- Source
- The Lancet; January 2024, Vol. 403 Issue: 10421 p31-43, 13p
- Subject
- Language
- ISSN
- 01406736; 1474547X